[
  {
    "id": "out-nsclc-egfr-osim-001",
    "text_summary": "A 58-year-old never-smoking Asian female with stage IV EGFR L858R-mutant lung adenocarcinoma was treated with first-line osimertinib. Baseline biomarkers included EGFR L858R, PD-L1 TPS 5%, no co-mutations in TP53 or STK11. The patient achieved a partial response (PR) by RECIST 1.1 at 8 weeks with 62% tumor shrinkage. Progression-free survival was 22 months. At progression, ctDNA analysis revealed acquired MET amplification (GCN 12) without EGFR C797S. Grade 2 rash and grade 1 diarrhea were the primary adverse events, managed with dose continuation. Brain MRI remained negative throughout treatment. The patient was subsequently enrolled on a clinical trial of osimertinib plus savolitinib for the MET-amplified resistance mechanism.",
    "case_id": "CASE-NSCLC-001",
    "cancer_type": "NSCLC",
    "stage": "IV",
    "therapy": "osimertinib",
    "response": "PR",
    "duration_months": 22,
    "pfs_months": 22,
    "os_months": 38,
    "toxicities": "grade 2 rash, grade 1 diarrhea",
    "biomarkers_at_baseline": "EGFR L858R, PD-L1 TPS 5%",
    "prior_therapies": "none"
  },
  {
    "id": "out-melanoma-braf-combo-002",
    "text_summary": "A 45-year-old male with BRAF V600E-mutant unresectable stage IIIC melanoma was treated with dabrafenib plus trametinib combination therapy. Baseline molecular profiling showed BRAF V600E, no NRAS co-mutation, CDKN2A loss, and TMB of 8 mut/Mb. The patient achieved complete response (CR) by 6 months. Treatment was continued for 24 months before disease progression in liver. At recurrence, biopsy showed NRAS Q61K acquisition. Pyrexia (grade 2) occurred in the first 3 months requiring dose interruption but resolved with rechallenge. The patient subsequently received nivolumab plus ipilimumab immunotherapy and achieved a durable partial response. Overall survival from initial diagnosis was 48 months and ongoing at last follow-up.",
    "case_id": "CASE-MEL-002",
    "cancer_type": "melanoma",
    "stage": "IIIC",
    "therapy": "dabrafenib + trametinib",
    "response": "CR",
    "duration_months": 24,
    "pfs_months": 24,
    "os_months": 48,
    "toxicities": "grade 2 pyrexia, grade 1 fatigue",
    "biomarkers_at_baseline": "BRAF V600E, CDKN2A loss, TMB 8 mut/Mb",
    "prior_therapies": "none"
  },
  {
    "id": "out-breast-her2-tdxd-003",
    "text_summary": "A 52-year-old female with HER2-positive (IHC 3+, FISH amplified) metastatic breast cancer progressed on trastuzumab plus pertuzumab plus docetaxel first-line and T-DM1 second-line. She was treated with trastuzumab deruxtecan (T-DXd) as third-line therapy. Partial response was achieved at 6 weeks with 55% tumor shrinkage including regression of liver metastases. PFS was 18 months. Grade 2 nausea and grade 1 fatigue were the primary adverse events. Notably, the patient developed grade 1 interstitial lung disease (ILD) at month 9, managed with dose interruption and glucocorticoids with successful rechallenge. Baseline NGS showed PIK3CA E545K co-mutation. At progression after 18 months, HER2 expression remained 3+ but with acquired MET amplification.",
    "case_id": "CASE-BREAST-003",
    "cancer_type": "breast",
    "stage": "IV",
    "therapy": "trastuzumab deruxtecan",
    "response": "PR",
    "duration_months": 18,
    "pfs_months": 18,
    "os_months": 30,
    "toxicities": "grade 2 nausea, grade 1 fatigue, grade 1 ILD",
    "biomarkers_at_baseline": "HER2 IHC 3+, FISH amplified, PIK3CA E545K",
    "prior_therapies": "trastuzumab + pertuzumab + docetaxel, T-DM1"
  },
  {
    "id": "out-crc-msih-pembro-004",
    "text_summary": "A 62-year-old male with microsatellite instability-high (MSI-H) metastatic colorectal cancer was treated with first-line pembrolizumab monotherapy per KEYNOTE-177 results. Baseline molecular profile included MLH1 promoter hypermethylation (sporadic dMMR), BRAF V600E, TMB 42 mut/Mb, and PD-L1 CPS 65. The patient achieved complete response at 12 months with resolution of all liver and peritoneal metastases. Treatment was continued for 2 years total. At 36 months from initiation, the patient remained in sustained complete response off therapy. Grade 2 hypothyroidism (immune-related) developed at month 4 and required levothyroxine replacement. Grade 1 pruritis was managed with topical agents. This case demonstrates the exceptional durability of immunotherapy response in MSI-H CRC.",
    "case_id": "CASE-CRC-004",
    "cancer_type": "colorectal",
    "stage": "IV",
    "therapy": "pembrolizumab",
    "response": "CR",
    "duration_months": 36,
    "pfs_months": 36,
    "os_months": 42,
    "toxicities": "grade 2 hypothyroidism (irAE), grade 1 pruritis",
    "biomarkers_at_baseline": "MSI-H, dMMR (MLH1 methylation), BRAF V600E, TMB 42 mut/Mb, PD-L1 CPS 65",
    "prior_therapies": "none"
  },
  {
    "id": "out-ovarian-brca-olaparib-005",
    "text_summary": "A 55-year-old female with BRCA1-mutant (germline c.5266dupC) stage IIIC high-grade serous ovarian cancer achieved complete response after primary debulking surgery and 6 cycles of carboplatin/paclitaxel. She was started on olaparib maintenance therapy. The patient remained in complete response for 48 months on olaparib maintenance before developing platinum-sensitive recurrence in the pelvis. Grade 2 anemia was the primary toxicity, managed with dose reduction from 300mg BID to 250mg BID. Grade 1 nausea resolved after the first 3 months. At recurrence, tissue biopsy showed a BRCA1 reversion mutation restoring the open reading frame. The patient received subsequent platinum-based rechallenge but with limited response, consistent with restored homologous recombination from the reversion mutation.",
    "case_id": "CASE-OVAR-005",
    "cancer_type": "ovarian",
    "stage": "IIIC",
    "therapy": "olaparib (maintenance)",
    "response": "CR",
    "duration_months": 48,
    "pfs_months": 48,
    "os_months": 72,
    "toxicities": "grade 2 anemia, grade 1 nausea",
    "biomarkers_at_baseline": "BRCA1 germline mutation (c.5266dupC), HRD score 58",
    "prior_therapies": "carboplatin + paclitaxel (6 cycles)"
  },
  {
    "id": "out-nsclc-alk-alectinib-006",
    "text_summary": "A 38-year-old never-smoking male with EML4-ALK fusion-positive stage IV lung adenocarcinoma with brain metastases was treated with first-line alectinib. Baseline profiling confirmed EML4-ALK variant 1 fusion by NGS, TP53 wild-type, PD-L1 TPS 0%. Brain MRI showed 3 small parenchymal metastases (largest 12mm). The patient achieved complete intracranial response by 8 weeks and systemic partial response with 70% tumor shrinkage. PFS was 32 months. Treatment was well tolerated with grade 1 constipation and grade 1 elevated CPK. At progression, tissue rebiopsy revealed ALK G1202R solvent-front resistance mutation. The patient transitioned to lorlatinib and achieved a second partial response. This case illustrates the paradigm of sequential ALK TKI therapy and the importance of resistance mutation profiling.",
    "case_id": "CASE-NSCLC-006",
    "cancer_type": "NSCLC",
    "stage": "IV",
    "therapy": "alectinib",
    "response": "PR",
    "duration_months": 32,
    "pfs_months": 32,
    "os_months": 54,
    "toxicities": "grade 1 constipation, grade 1 elevated CPK",
    "biomarkers_at_baseline": "EML4-ALK fusion (variant 1), TP53 wild-type, PD-L1 TPS 0%",
    "prior_therapies": "none"
  },
  {
    "id": "out-pancreatic-brca2-olaparib-007",
    "text_summary": "A 63-year-old female with germline BRCA2-mutant metastatic pancreatic adenocarcinoma was treated with first-line FOLFIRINOX (8 cycles) achieving partial response. She was then transitioned to olaparib maintenance therapy per the POLO trial paradigm. The patient maintained stable disease on olaparib maintenance for 12 months with grade 1 fatigue and grade 1 nausea as the primary adverse events. At month 12, CT scan showed progressive disease in liver metastases. Overall survival from diagnosis of metastatic disease was 28 months. ctDNA analysis at progression showed the original BRCA2 mutation at reduced VAF but no reversion mutations detected. The patient was subsequently treated with gemcitabine plus nab-paclitaxel as second-line therapy. This case illustrates the role of olaparib maintenance after platinum response in BRCA-mutant pancreatic cancer.",
    "case_id": "CASE-PANC-007",
    "cancer_type": "pancreatic",
    "stage": "IV",
    "therapy": "olaparib (maintenance after FOLFIRINOX)",
    "response": "SD",
    "duration_months": 12,
    "pfs_months": 12,
    "os_months": 28,
    "toxicities": "grade 1 fatigue, grade 1 nausea",
    "biomarkers_at_baseline": "BRCA2 germline mutation, KRAS G12D",
    "prior_therapies": "FOLFIRINOX (8 cycles)"
  },
  {
    "id": "out-nsclc-kras-sotorasib-008",
    "text_summary": "A 67-year-old male former smoker with KRAS G12C-mutant stage IV lung adenocarcinoma progressed on first-line carboplatin/pemetrexed/pembrolizumab after 8 months. He was treated with sotorasib as second-line therapy. The patient achieved partial response at 6 weeks with 40% tumor shrinkage. PFS was 8 months. Grade 2 diarrhea and grade 3 elevated ALT required dose interruption at month 3, with resumption at reduced dose after liver enzyme normalization. At progression, ctDNA revealed KRAS Y96D secondary mutation and MET amplification (GCN 8). STK11 and TP53 co-mutations were present at baseline and likely contributed to the limited immunotherapy benefit in the first-line setting. The patient was subsequently enrolled in a clinical trial evaluating a next-generation KRAS inhibitor.",
    "case_id": "CASE-NSCLC-008",
    "cancer_type": "NSCLC",
    "stage": "IV",
    "therapy": "sotorasib",
    "response": "PR",
    "duration_months": 8,
    "pfs_months": 8,
    "os_months": 20,
    "toxicities": "grade 2 diarrhea, grade 3 elevated ALT",
    "biomarkers_at_baseline": "KRAS G12C, STK11 mutation, TP53 mutation, PD-L1 TPS 1%",
    "prior_therapies": "carboplatin + pemetrexed + pembrolizumab"
  },
  {
    "id": "out-aml-idh1-ivosidenib-009",
    "text_summary": "A 74-year-old male with newly diagnosed IDH1 R132H-mutant AML, ineligible for intensive chemotherapy, was treated with ivosidenib plus azacitidine. Baseline characterization showed IDH1 R132H (VAF 38%), NPM1 wild-type, FLT3 wild-type, intermediate-risk cytogenetics. The patient achieved complete remission with incomplete hematologic recovery (CRi) by cycle 3. D-2-hydroxyglutarate levels decreased by 95%. The patient maintained CRi for 14 months before developing disease progression with blast increase. Differentiation syndrome (grade 2) occurred in cycle 1 requiring dexamethasone treatment. Grade 1 QTc prolongation was monitored but did not require dose modification. At relapse, repeat molecular testing revealed IDH2 R140Q emergence (isoform switch) as the resistance mechanism. This case demonstrates the efficacy and limitations of IDH-targeted therapy in elderly AML patients.",
    "case_id": "CASE-AML-009",
    "cancer_type": "AML",
    "stage": "newly diagnosed",
    "therapy": "ivosidenib + azacitidine",
    "response": "CR",
    "duration_months": 14,
    "pfs_months": 14,
    "os_months": 22,
    "toxicities": "grade 2 differentiation syndrome, grade 1 QTc prolongation",
    "biomarkers_at_baseline": "IDH1 R132H (VAF 38%), NPM1 wild-type, FLT3 wild-type",
    "prior_therapies": "none"
  },
  {
    "id": "out-chol-fgfr2-pemigatinib-010",
    "text_summary": "A 56-year-old female with FGFR2-BICC1 fusion-positive intrahepatic cholangiocarcinoma, previously treated with gemcitabine plus cisplatin, was treated with pemigatinib. Molecular profiling confirmed FGFR2-BICC1 fusion by RNA-based NGS, with co-alterations in CDKN2A loss and BAP1 mutation. The patient achieved partial response at 8 weeks with 45% tumor shrinkage and significant improvement in cancer-related symptoms. PFS was 9 months. Grade 3 hyperphosphatemia was managed with phosphate binders and low-phosphate diet. Serous retinal detachment (grade 2) developed at month 5, requiring temporary dose hold with complete resolution. At progression, ctDNA analysis revealed an FGFR2 V564F gatekeeper mutation. The patient was transitioned to futibatinib (covalent FGFR inhibitor) with initial stable disease. This case illustrates the paradigm of targeted therapy in FGFR2 fusion-positive biliary tract cancer.",
    "case_id": "CASE-CHOL-010",
    "cancer_type": "cholangiocarcinoma",
    "stage": "IV",
    "therapy": "pemigatinib",
    "response": "PR",
    "duration_months": 9,
    "pfs_months": 9,
    "os_months": 18,
    "toxicities": "grade 3 hyperphosphatemia, grade 2 serous retinal detachment",
    "biomarkers_at_baseline": "FGFR2-BICC1 fusion, CDKN2A loss, BAP1 mutation",
    "prior_therapies": "gemcitabine + cisplatin"
  },
  {
    "id": "out-prostate-brca-olaparib-011",
    "text_summary": "A 71-year-old male with BRCA2-mutant metastatic castration-resistant prostate cancer (mCRPC) was treated with olaparib after progression on enzalutamide and one prior taxane (docetaxel). Somatic tumor profiling confirmed biallelic BRCA2 loss (germline frameshift + somatic LOH), with ATM wild-type and low TMB (2 mut/Mb). The patient achieved confirmed partial response (PSA decline >50%, measurable disease regression) with radiographic improvement at 12 weeks. PFS was 10 months. Grade 2 anemia required transfusion support on two occasions. Grade 1 nausea was managed supportively. At progression, PSA rose with new bone metastases. The patient was enrolled on a trial of olaparib plus an AKT inhibitor. This case from the PROfound trial paradigm demonstrates olaparib activity in BRCA2-mutant mCRPC, the population with the strongest PARP inhibitor benefit in prostate cancer.",
    "case_id": "CASE-PROST-011",
    "cancer_type": "prostate",
    "stage": "IV (mCRPC)",
    "therapy": "olaparib",
    "response": "PR",
    "duration_months": 10,
    "pfs_months": 10,
    "os_months": 24,
    "toxicities": "grade 2 anemia (requiring transfusion), grade 1 nausea",
    "biomarkers_at_baseline": "BRCA2 biallelic loss (germline + somatic LOH), ATM wild-type, TMB 2 mut/Mb",
    "prior_therapies": "enzalutamide, docetaxel"
  },
  {
    "id": "out-nsclc-pdl1-pembro-chemo-012",
    "text_summary": "A 60-year-old male current smoker with stage IV lung adenocarcinoma, EGFR/ALK/ROS1 wild-type, PD-L1 TPS 30%, was treated with first-line carboplatin plus pemetrexed plus pembrolizumab followed by pembrolizumab plus pemetrexed maintenance. Molecular profiling showed KRAS G12V, TP53 R248W, STK11 wild-type, TMB 14 mut/Mb. The patient achieved partial response at 9 weeks. After 4 cycles of induction, transitioned to maintenance with ongoing PR. The patient developed grade 2 immune-mediated hepatitis at month 8, managed with pembrolizumab hold and prednisone taper, with successful rechallenge. PFS was 14 months. Progressive disease was detected in adrenal glands at month 14. Grade 1 fatigue and grade 1 nausea were present throughout treatment. Overall survival was 26 months. This case represents a typical outcome for PD-L1-intermediate NSCLC treated with chemoimmunotherapy.",
    "case_id": "CASE-NSCLC-012",
    "cancer_type": "NSCLC",
    "stage": "IV",
    "therapy": "carboplatin + pemetrexed + pembrolizumab, then pembrolizumab + pemetrexed maintenance",
    "response": "PR",
    "duration_months": 14,
    "pfs_months": 14,
    "os_months": 26,
    "toxicities": "grade 2 immune hepatitis (irAE), grade 1 fatigue, grade 1 nausea",
    "biomarkers_at_baseline": "KRAS G12V, TP53 R248W, STK11 wild-type, PD-L1 TPS 30%, TMB 14 mut/Mb",
    "prior_therapies": "none"
  }
]
